Against Evidential Pluralism in Pharmaceutical Regulation
Philosophy of Science · 2023-12 · 90 (5) · 1276-1285
DOI: 10.1017/psa.2023.40 ↗Kurz gefasst
Fachartikel in der Zeitschrift Philosophy of Science, online erschienen am 23.02.2023. Verfasst von Doohyun Sung und 1 weiteren Autor:innen. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
We examine arguments regarding the use of mechanistic evidence in assessing treatment efficacy and find that advocates and critics of EBM+ have largely been talking past each other due to a difference in focus. We explore aducanumab for the treatment of Alzheimer’s disease as a case that may speak to the role of EBM+ in pharmaceutical regulation. The case suggests the debate may be more fruitful if philosophers confine debates to particular domains of medicine and weigh in prospectively instead of relying on historical cases in which outcomes are known and that are susceptible to hindsight bias.
Zitieren
APA
Sung, D., & Holman, B. (2023). Against Evidential Pluralism in Pharmaceutical Regulation. Philosophy of Science, 90(5), 1276-1285. https://doi.org/10.1017/psa.2023.40
Vancouver
Sung D, Holman B. Against Evidential Pluralism in Pharmaceutical Regulation. Philosophy of Science. 2023;90(5):1276-1285. doi:10.1017/psa.2023.40
BibTeX
@article{Sung2023,
author = {Sung, Doohyun and Holman, Bennett},
title = {Against Evidential Pluralism in Pharmaceutical Regulation},
journal = {Philosophy of Science},
year = {2023},
volume = {90},
number = {5},
pages = {1276--1285},
doi = {10.1017/psa.2023.40}
}
EUVIMED